International Journal of Medical, Pharmacy and Drug Research (IJMPD)
DOI: https://dx.doi.org/10.22161/ijmpd.8.1
Peer-Reviewed Journal
Int. J. Med. Phar. Drug Re., 8(1), 2024
ISSN: 2456-8015

GENE Therapy: A Review

Simranjit Kaur *, Rajesh Kumar, Ajeet Pal Singh, Amar Pal Singh, Meenakshi Malhotra

Department of Pharmacy, St. Soldier Institute of Pharmacy, Lidhran campus, Behind NIT(R.E.C.),Jalandhar-Amritsar Bypass, Nh-1, Jalandhar-144011, Punjab, India

*Address for correspondence: Department of Pharmacy, St. Soldier Institute of Pharmacy, Lidhran campus, Behind Nit (R.E.C), Jalandhar-Amritsar Bypass, NH-1, Jalandhar-144011, Punjab, India

Email: sk8056063@gmail.com

Received: 08 Feb 2024; Received in revised form:15 Mar 2024; Accepted: 22 Mar 2024; Available online: 31 Mar 2024

Abstract *— Gene therapy, a revolutionary approach to treating genetic disorders, holds tremendous promise in offering targeted and potentially curative treatments for a wide range of diseases. This paper provides an overview of the principles, techniques, and recent advancements in gene therapy. It begins with an introduction to the concept of gene therapy, elucidating its underlying mechanisms and various delivery methods, including viral vectors, non-viral vectors, and genome editing tools such as CRISPR-Cas9. The paper then discusses the applications of gene therapy in treating genetic disorders, including but not limited to hemophilia, cystic fibrosis, muscular dystrophy, and certain types of cancer. By correcting or replacing faulty genes, gene therapy has the potential to alleviate symptoms, halt disease progression, and even restore normal cellular function. This therapeutic strategy involves delivering functional genes into target cells to restore normal cellular function. Utilizing viral vectors or non-viral methods, gene therapy can potentially treat a wide range of diseases, including inherited disorders like cystic fibrosis, muscular dystrophy, and hemophilia, as well as certain types of cancer and cardiovascular diseases. Clinical trials have demonstrated both the safety and efficacy of gene therapy in various contexts, although challenges such as immune responses, delivery efficiency, and long-term gene expression persist. Continued research and technological advancements are essential to overcome these hurdles and unlock the full potential of gene therapy as a transformative medical intervention. Furthermore, this paper highlights recent breakthroughs and clinical successes in the field of gene therapy, showcasing notable case studies and trials that demonstrate its efficacy and safety. These advancements underscore the growing momentum and optimism surrounding gene therapy as a viable treatment option for previously incurable conditions. In conclusion, gene therapy represents a paradigm shift in medicine, offering hope for individuals affected by genetic disorders and opening new avenues for personalized and precision medicine. With continued research, collaboration, and investment, gene therapy holds the potential to transform the landscape of healthcare, ultimately improving patient outcomes and quality of life.*

Keywords *— **Gene Therapy, Genetic Disorders Treatment, Viral Vectors, CRISPR-Cas9, Clinical Trials***

I. INTRODUCTION

Gene therapy, a groundbreaking field at the intersection of molecular biology, genetics, and medicine, holds immense promise for revolutionizing the treatment of genetic disorders and various other diseases. This introduction

provides an overview of the fundamental concepts, historical evolution, and current landscape of gene therapy, along with key references highlighting significant milestones and advancements in the field.

At its core, gene therapy aims to correct or modulate genetic defects by introducing therapeutic genes, modifying existing genes, or regulating gene expression within target cells. By harnessing the power of genetic engineering, gene therapy offers the potential to address the root causes of diseases at the molecular level, thereby providing targeted and potentially curative treatments.

The roots of gene therapy can be traced back to the 1960s, with the pioneering work of researchers such as Friedmann and Roblin, who proposed the concept of using genetic material to treat inherited disorders. Over subsequent decades, advances in molecular biology, recombinant DNA technology, and viral vector development paved the way for experimental gene therapy trials in animal models and eventually in human patients.

The landmark clinical trial conducted by French researchers in 1990, which involved the first successful gene therapy treatment for severe combined immunodeficiency (SCID), marked a significant milestone in the field. This groundbreaking achievement demonstrated the feasibility and potential therapeutic benefits of gene therapy in humans, sparking widespread interest and investment in the field.

Since then, gene therapy has evolved rapidly, with ongoing research efforts focused on refining delivery methods, enhancing vector efficiency and specificity, and addressing safety and regulatory concerns. The advent of genome editing technologies, particularly CRISPR-Cas9, has further accelerated progress in gene therapy, enabling precise and targeted modifications of the genome with unprecedented accuracy.

This introduction sets the stage for exploring the various aspects of gene therapy, including its mechanisms of actioinspiren, applications across different disease categories, clinical successes, challenges, and future directions. By providing insights into the transformative potential of gene therapy, this introduction aims to further exploration and innovation in this dynamic field of medicine.

Definition :

Gene therapy is a therapeutic approach that involves the delivery of genetic material into a patient's cells to treat or prevent disease. The genetic material may be intended to replace, augment, or regulate the function of a defective gene, or to introduce new functions into the cells. This approach aims to address the underlying causes of diseases at the molecular level, offering the potential for long-term or even permanent treatment solutions.

It aimed at treating or preventing diseases by introducing, removing, or altering genetic material within a person's cells. This genetic material can include therapeutic genes designed to replace or supplement defective genes, inhibit the expression of harmful genes, or introduce new functions to cells.

Principle:

The principle of gene therapy revolves around correcting faulty genes or introducing therapeutic genes into a patient's cells to treat or prevent disease.

1. **Identifying the Target Gene**: The first step is to identify the specific gene or genes that are causing the disease or contributing to its progression.

2. **Delivery System**: Once the target gene is identified, the next step is to deliver the therapeutic gene to the appropriate cells in the patient's body. This can be achieved using various delivery systems, such as viral vectors (e.g., adenovirus, lentivirus) or non-viral vectors (e.g., liposomes, nanoparticles).

3. **Integration or Expression of Therapeutic Gene**: The therapeutic gene must be integrated into the genome of the target cells or expressed transiently to produce the desired therapeutic effect. Integration ensures stable, long-term expression of the therapeutic gene.

4. **Monitoring and Regulation**: Gene therapy often requires careful monitoring of the patient's condition to assess the effectiveness and safety of the treatment. This may involve regular check-ups, imaging studies, and laboratory tests.

5. **Potential Challenges**: There are several challenges associated with gene therapy, including immune responses to the therapeutic vector, off-target effects, and the risk of unintended gene mutations. Researchers continually work to overcome these challenges through advancements in vector design, delivery methods, and gene editing technologies.

II. TYPES OF GENE THERAPY

1. **Gene Replacement Therapy**: Gene replacement therapy involves introducing a functional copy of a defective gene into the patient's cells to replace or supplement the faulty gene.

2. **Gene Addition Therapy**: Gene addition therapy aims to introduce a new functional gene into the patient's cells without altering or replacing the existing genes. This approach can provide therapeutic benefits by supplementing the cellular machinery with additional genetic material.

3. **Gene Editing Therapy:** Gene editing therapy involves precise modification of the patient's DNA sequence to correct genetic mutations or introduce desired changes using genome editing tools like CRISPR-Cas9.

4. **Gene Suppression Therapy:** Gene suppression therapy aims to reduce the expression or activity of a specific gene associated with disease by using techniques such as RNA interference (RNAi) or antisense oligonucleotides.

5. **Immunogene Therapy:** Immunogene therapy involves modifying immune cells, such as T cells or dendritic cells, to enhance their anti-tumor or anti-pathogen activity through genetic engineering.

Steps involved in gene therapy :

1. **Identifying the Target Gene**: This involves identifying the specific gene responsible for the disorder through genetic testing and analysis.

2. **Designing the Therapeutic Gene**: Scientists design the therapeutic gene that will either replace the faulty gene or provide the correct version of the gene.

3. **Vector Selection**: Selection of suitable viral or non-viral vectors for delivering the therapeutic gene into target cells.

4. **Gene Insertion into Vector**: Insertion of the therapeutic gene into the selected vector using molecular biology techniques.

5. **Vector Production**: Large-scale production of the viral vectors for clinical use through cell culture techniques.

6. **Administering the Vector**: Delivery of the vector carrying the therapeutic gene to the patient, which can be done through various routes such as direct injection or intravenous infusion.

7. **Cellular Uptake and Expression**: The therapeutic gene is taken up by target cells, and its expression leads to the production of the desired protein, correcting the genetic defect.

8. **Monitoring and Follow-Up**: Close monitoring of patients to assess the effectiveness and safety of gene therapy, along with long-term follow-up to evaluate outcomes and potential side effects.

III. APPLICATIONS

1. **Treatment of Genetic Disorders**: Gene therapy offers potential cures or symptom alleviation for various genetic diseases, including cystic fibrosis, hemophilia, muscular dystrophy, and sickle cell anemia.

2. **Cancer Therapy**: Gene therapy strategies are being developed to target cancer cells by delivering therapeutic genes, inducing apoptosis, modulating immune responses, or sensitizing tumors to chemotherapy and radiation therapy.

3. **Treatment of Neurological Disorders**: Gene therapy holds promise for treating neurodegenerative diseases such as Parkinson's disease, Alzheimer's disease, Huntington's disease, and amyotrophic lateral sclerosis (ALS) by delivering therapeutic genes or modulating gene expression.

4. **Treatment of Infectious Diseases**: Gene therapy can be used to enhance the immune response against infectioand us agents, develop vaccines, or introduce therapeutic genes targeting pathogens, such as HIV, hepatitis B and C viruses, and malaria.

5. **Treatment of Cardiovascular Disorders**: Gene therapy approaches are being explored for treating cardiovascular diseases such as coronary artery

disease, heart failure, and inherited cardiomyopathies by delivering therapeutic genes to cardiac tissues.

6. **Inherited Eye Disorders**: Gene therapy has shown promise in treating inherited retinal diseases such as Leber congenital amaurosis retinitis pigmentosa by delivering functional genes to the retina.

Vectors in gene therapy :

1. **Viral Vectors**:

- **Adenoviral Vectors** (**AdV**): Adenoviruses are often used as vectors due to their ability to efficiently infect a wide range of cell types and their capacity to accommodate large DNA inserts.

- **Adeno-Associated Viral Vectors** (**AAV**): AAVs are popular vectors due to their ability to infect both dividing and non-dividing cells, low immunogenicity, and long-term gene expression.

- **Lentiviral Vectors**: Lentiviruses, such as HIV-derived lentiviral vectors, are capable of integrating their genetic material into the host genome, allowing stable and long-term gene expression.

- **Retroviral Vectors**: Retroviruses can integrate their genetic material into the host genome and are used for delivering therapeutic genes to dividing cells.

2. Non-viral Vectors:

- **Lipid-Based Vectors**: Liposomes and lipid nanoparticles are commonly used non-viral vectors due to their biocompatibility, ease of preparation, and ability to encapsulate and deliver nucleic acids.

- **Polymer-Based Vectors**: Polymers such as polyethyleneimine (PEI) and polyethyleneglycol (PEG) can form complexes with DNA or RNA and protect them from degradation, facilitating cellular uptake and gene expression.

	ADENOVIRUS	AAV	γ-RETROVIRUS	LENTIVIRUS
SIZE	~90-100 nm	~25 nm	~80-100 nm	~80-100 nm
GENOME	dsDNA	ssDNA	ssRNA	ssRNA
PACKAGING CAPACITY	~8 kb – 36 kb	~4.7 kb	10 kb	8 kb
TRANSDUCTION	Dividing and non-dividing cells	Dividing and non-dividing cells	Dividing cells	Dividing and non-dividing cells
TRANSDUCTION EFFICIENCY	High	Moderate	Moderate	Moderate
INTEGRATION	Non-integrating	Non-integrating	Integrating	Integrating
EXPRESSION	Transient	Transient or stable	Stable	Stable
BIOSAFETY LEVEL	BSL-2	BSL-1	BSL-2	BSL-2
IMMUNOGENICITY	High	Low	Moderate-High	Moderate-High
GENE THERAPY STRATEGY	*In vivo*	*In vivo*	*Ex vivo*	*Ex vivo*

Type of Vectors	Advantages	Disadvantages
Viral vectors	High gene transduction efficiency Transgene expression can be controlled by virus (transient expression or persistent expression) Can target specific cell types such as dividing cells or non-dividing cells [33,57]	Difficult to manufacture, produced in low virus titers Immune reactions to virus [56] Limitation in packaging capacity e.g., 4.5 kb for AAV vectors [33,57] Safety concerns e.g., insertion mutagenesis [58]
Non-viral vectors	Simple manufacturing Low cost Low immunogenicity High packaging capacity	Low in vivo gene transduction efficiency [57] High quantity for therapeutic effects Cannot target specific cell types Toxicity related to materials [34]

Advantages:

1. **Potential Cure for Genetic Disorders**:Gene therapy offers the potential to treat or cure genetic diseases by correcting the underlying genetic defects. This could lead to long-term or even permanent relief from symptoms.

2. **Targeted Treatment**: Gene therapy can target specific cells or tissues affected by the disease, minimizing off-target effects and reducing systemic toxicity compared to conventional treatments like chemotherapy.

3. **Personalized Medicine**:Gene therapy can be tailored to an individual's genetic makeup, allowing for personalized treatment strategies that take into account the unique genetic mutations causing their disease.

4. **Single Treatment**: In some cases, a single administration of the therapeutic gene may provide long- lasting or permanent benefits, reducing the need for repeated treatments and improving patient compliance.

5. **Potential for Treating Complex Diseases**: Gene therapy has the potential to address complex diseases with multifactorial causes, such as cancer and cardiovascular disorders, by targeting multiple genes or pathways involved in the disease process.

Disadvantages:

1. **Immune Response**: The body may mount immune responses against the viral vectors or the therapeutic proteins produced by the inserted genes, leading to inflammation, tissue damage, or loss of therapeutic efficacy.

2. **Insertional Mutagenesis**: In some cases, integrating viral vectors may disrupt the host genome, leading to insertional mutagenesis and potentially causing unintended genetic alterations or oncogenesis.

3. **Limited Efficiency**: Gene delivery methods may have limited efficiency in reaching target cells or achieving sufficient levels of gene expression to produce therapeutic effects, especially in tissues with barriers such as the blood-brain barrier.

4. **Safety Concerns**:Despite significant progress, gene therapy still faces safety concerns related to the potential for off-target effects, unintended gene silencing, or unintended consequences of modifying gene expression.

5. **Complexity and Cost**: Gene therapy is a complex and technically demanding treatment that requires specialized expertise, infrastructure, and resources. The high cost of development, production, and administration may limit accessibility for some patients.

Challenges include:

1. Immune Response: The immune system can recognize viral vectors used in gene therapy as foreign invaders, leading to immune responses that may reduce the effectiveness of the therapy or cause adverse reactions. This can include neutralizing antibodies against the vector, activation of T cells, or inflammation at the site of vector administration.

2. Off-Target Effects: Gene editing technologies such as CRISPR-Cas9 may result in unintended modifications to the genome, leading to off-target effects that could have unpredictable consequences, including the potential to cause cancer or other genetic abnormalities.

3. Vector Toxicity: Some viral vectors used in gene therapy may induce toxic effects in target cells or tissues, limiting their therapeutic potential. Additionally, the integration of viral vectors into the host genome can disrupt normal gene function and lead to adverse effects.

4. Limited Transgene Expression: Achieving sustained and therapeutic levels of transgene expression in target cells remains a challenge, particularly in tissues with rapid turnover or those protected by biological barriers, such as the blood-brain barrier.

5. Regulatory Hurdles: Gene therapy involves complex regulatory processes, including preclinical testing, clinical trial approval, and post-market surveillance. Regulatory agencies must balance the need for safety and efficacy with the urgency to bring potentially life-saving treatments to patients in a timely manner.

IV. RECENT DEVELOPMENTS:

1. **Advancements in Gene Editing Technologies**: CRISPR-Cas9 and other gene editing tools have seen significant advancements, enabling precise

genome editing for therapeutic purposes. Researchers have developed improved delivery methods and enhanced editing efficiency, opening up new possibilities for treating genetic disorders.

2. **Expansion of Clinical Trials**: Gene therapy clinical trials have expanded globally, covering a wide range of diseases, including rare genetic disorders, cancer, neurodegenerative diseases, and infectious diseases. These trials evaluate the safety and efficacy of novel gene therapy approaches in human patients.

3. **Emerging Therapeutic Targets**: Researchers are exploring novel therapeutic targets and disease pathways for gene therapy intervention. This includes targeting specific genetic mutations, modulating immune responses, and developing gene therapies for complex diseases with multifactorial etiology.

4. **Improved Vector Design and Delivery Methods**: Advances in vector design and delivery technologies have enhanced the safety, efficiency, and specificity of gene therapy. This includes the development of novel viral vectors, engineered nanoparticles, and exosome-based delivery systems.

5. **Regulatory Approvals and Commercialization**: Several gene therapies have received regulatory approvals in various countries, marking significant milestones in the field. Commercialization efforts have also intensified, with gene therapy products entering the market for the treatment of specific diseases.

Techniques and approaches for future detection of gene therapy:

1. Molecular Assays: Polymerase chain reaction (PCR) and quantitative PCR (qPCR) can be used to detect and quantify the presence of therapeutic genes or gene expression levels in treated cells or tissues. These assays provide valuable information about the persistence and activity of the introduced genes.

2. Next-Generation Sequencing (NGS): NGS technologies enable comprehensive analysis of the genome, transcriptome, and epigenome, allowing researchers to detect genetic alterations, insertions, deletions, and other modifications resulting from gene therapy. Whole-genome sequencing and RNA sequencing can provide insights into the integration sites of therapeutic genes and potential off-target effects.

3. Imaging Techniques: Non-invasive imaging modalities such as positron emission tomography (PET), single-photon emission computed tomography (SPECT), magnetic resonance imaging (MRI), and bioluminescence imaging (BLI) can be used to visualize and track the distribution, expression, and function of transgenes in living organisms over time.

4. Biomarker Analysis: Monitoring specific biomarkers associated with the disease phenotype or therapeutic response can provide valuable information about the effectiveness of gene therapy. Biomarkers may include levels of secreted proteins, metabolites, or cellular markers indicative of disease progression or regression.

5. Immunological Assays: Immune responses to gene therapy vectors and transgenes can be assessed using immunological assays such as enzyme-linked immunosorbent assays (ELISA), flow cytometry, and cytokine profiling. Detection of anti-vector antibodies or cell-mediated immune responses can inform on potential immunogenicity and safety concerns.

6. Longitudinal Clinical Follow-up: Long-term monitoring of patients receiving gene therapy is essential for assessing the durability of therapeutic effects, detecting late-onset adverse events, and evaluating the overall safety and efficacy of the treatment. Clinical follow-up may include physical examinations, laboratory tests, and patient-reported outcomes.

7. Bioinformatics and Computational Analyses: Advanced computational tools and bioinformatics algorithms can aid in the analysis and interpretation of high-throughput data generated from gene therapy studies. Integration of omics data, network analysis, and machine learning approaches can help identify patterns, correlations, and predictive biomarkers associated with treatment outcomes.

V. CONCLUSION

Gene therapy represents a groundbreaking approach in the treatment of genetic and acquired

diseases by directly addressing the underlying genetic causes. Its development and implementation have been marked by significant challenges, including delivery methods, immune responses, and ethical concerns. However, ongoing research and technological advancements have continued to overcome many of these obstacles, leading to successful treatments for a range of conditions that were previously thought to be untreatable.

As we look to the future, gene therapy holds the promise of offering definitive cures for a wide array of diseases, including inherited disorders, certain types of cancer, and viral infections. The approval of gene therapy products for clinical use in various parts of the world is a testament to its potential. For instance, treatments such as Luxturna for inherited retinal disease, Zolgensma for spinal muscular atrophy, and CAR-T cell therapies for certain leukemias and lymphomas have demonstrated remarkable efficacy, highlighting the potential of gene therapy to change the landscape of medicine.

Future research is likely to focus on improving delivery mechanisms, minimizing immune responses, enhancing specificity and safety, and making gene therapy more accessible and affordable. Innovations such as CRISPR-Cas9 and other gene editing technologies offer exciting prospects for more precise and efficient gene correction methods. Furthermore, regulatory frameworks are evolving to support the rapid development and safe deployment of gene therapy treatments.

In conclusion, gene therapy stands at the forefront of personalized medicine, offering hope for patients with previously incurable diseases. Its continued evolution will undoubtedly hinge on interdisciplinary collaboration, ethical considerations, and technological innovations, promising to redefine our approach to medicine and healthcare.

REFERENCES

[1] Gaudet D, Méthot J, Déry S, et al. Efficacy and long-term safety of alipogene tiparvovec (AAV1- LPLS447X) gene therapy for lipoprotein lipase deficiency: an open-label trial. Gene Ther. 2013;20(4):361-369. doi:10.1038/gt.2012.89

[2] Hacein-Bey-Abina, S., Garrigue, A., Wang, G. P., Soulier, J., Lim, A., Morillon, E., ... & Cavazzana- Calvo, M. (2008). Insertional oncogenesis in 4 patients after retrovirus-mediated gene therapy of SCID- X1. The Journal of clinical investigation, 118(9), 3132-3142.

[3] Mendell JR, Al-Zaidy S, Shell R, et al. Single-Dose Gene-Replacement Therapy for Spinal Muscular Atrophy. N Engl J Med. 2017;377(18):1713-1722. doi:10.1056/NEJMoa1706198

[4] Tebas P, Stein D, Tang WW, et al. Gene Editing of CCR5 in Autologous CD4 T Cells of Persons Infected with HIV. N Engl J Med. 2014;370(10):901-910. doi:10.1056/NEJMoa1300662.

[5] Friedmann T, Roblin R. Gene Therapy for Human Genetic Disease? Science. 1972;175(4025):949-955. doi:10.1126/science.175.4025.949

[6] Cavazzana-Calvo M, Hacein-Bey S, de Saint Basile G, et al. Gene Therapy of Human Severe Combined Immunodeficiency (SCID)-X1 Disease. Science. 2000;288(5466):669-672. doi:10.1126/science.288.5466.669.

[7] National Institutes of Health (NIH). (2021). What is gene therapy? Retrieved from https://ghr.nlm.nih.gov/primer/therapy/genetherapyReferences:

[8] Crystal, R. G. (1995). Transfer of genes to humans: early lessons and obstacles to success. Science, 270(5235), 404-410.

[9] "Gene Therapy: Principles and Challenges" by Christof von Kalle and Cynthia E. Dunbar.

[10] Gaudet D, Méthot J, Déry S, et al. Efficacy and long-term safety of alipogene tiparvovec (AAV1-LPLS447X) gene therapy for lipoprotein lipase deficiency: an open-label trial. Gene Ther. 2013;20(4):361-369. doi:10.1038/gt.2012.89

[11] Hacein-Bey-Abina S, Garrigue A, Wang GP, et al. Insertional oncogenesis in 4 patients after retrovirus-mediated gene therapy of SCID-X1. J Clin Invest. 2008;118(9):3132-3142. doi:10.1172/JCI35700

[12] Tebas P, Stein D, Tang WW, et al. Gene editing of CCR5 in autologous CD4 T cells of persons infected with HIV. N Engl J Med. 2014;370(10):901-910. doi:10.1056/NEJMoa1300662

[13] Finkel RS, Mercuri E, Darras BT, et al. Nusinersen versus Sham Control in Infantile-Onset Spinal Muscular Atrophy. N Engl J Med. 2017;377(18):1723-1732. doi:10.1056/NEJMoa1702752

[14] Maude SL, Laetsch TW, Buechner J, et al. Tisagenlecleucel in Children and Young Adults with B-Cell Lymphoblastic Leukemia. N Engl J Med. 2018;378(5):439-448. doi:10.1056/NEJMoa1709866

[15] National Institutes of Health (NIH). (2021). Genetic Testing. https://ghr.nlm.nih.gov/primer/testing/genetictesting.

[16] Gaj, T., Gersbach, C. A., & Barbas, C. F. (2013). ZFN, TALEN, and CRISPR/Cas-based methods for genome engineering. Trends in Biotechnology, 31(7), 397-405.

[17] Naldini, L. (2015). Gene therapy returns to centre stage. Nature, 526(7573), 351-360.

[18] Hacein-Bey-Abina, S., Von Kalle, C., Schmidt, M., Le Deist,

F., Wulffraat, N., McIntyre, E., ... & Fischer, A. (2003). LMO2-associated clonal T cell proliferation in two patients after gene therapy for SCID-X1. Science, 302(5644), 415-419.
[19] Mingozzi, F., & High, K. A. (2011). Therapeutic in vivo gene transfer for genetic disease using AAV: progress and challenges. Nature Reviews Genetics, 12(5), 341-355.
[20] Cao, O., Hoffman, B. E., & Moghimi, B. (2009). Impact of the underlying mutation and the route of vector administration on immune responses to factor IX in gene therapy for hemophilia B. Molecular Therapy, 17(10), 1733-1742.
[21] Ginn, S. L., Amaya, A. K., Alexander, I. E., & Edelstein, M. (2018). Gene therapy clinical trials worldwide to 2017: An update. Journal of Gene Medicine, 20(5), e3015.
[22] Srivastava, A., & Carter, B. J. (2017). AAV infection: protection from cancer. Human Gene Therapy, 28(4), 323-327.
[23] High, K. A., & Roncarolo, M. G. (2019). Gene Therapy. New England Journal of Medicine, 381(5), 455-464. [DOI: 10.1056/NEJMra1706910].
[24] Ribas, A., & Wolchok, J. D. (2018). Cancer immunotherapy using checkpoint blockade. Science, 359(6382), 1350-1355. [DOI: 10.1126/science.aar4060]
[25] Simonato, M., Bennett, J., Boulis, N. M., Castro, M. G., Fink, D. J., Goins, W. F., ... & Vandenberghe, L. H. (2013). Progress in gene therapy for neurological disorders. Nature Reviews Neurology, 9(5), 277-291. [DOI: 10.1038/nrneurol.2013.56]
[26] Kay, M. A., & Walker, B. D. (2001). Engineering cellular resistance to HIV. Nature Biotechnology, 19(3), 196-197. [DOI: 10.1038/85670]
[27] Hammond, H. K., Penny, W. F., Traverse, J. H., Henry, T. D., Watkins, M. W., Yancy, C. W., ... & Bass, T. (2016). Intracoronary gene transfer of adenylyl cyclase 6 in patients with heart failure: a randomized clinical trial. JAMA Cardiology, 1(2), 163-171. [DOI: 10.1001/jamacardio.2016.0008].
[28] Russell, S., Bennett, J., Wellman, J. A., Chung, D. C., Yu, Z. F., Tillman, A., ... & Maguire, A. M. (2017). Efficacy and safety of voretigene neparvovec (AAV2-hRPE65v2) in patients with RPE65- mediated inherited retinal dystrophy: a randomised, controlled, open-label, phase 3 trial. The Lancet, 390(10097), 849-860. [DOI: 10.1016/S0140-6736(17)31868-8].
[29] Mingozzi, F., & High, K. A. (2011). Therapeutic in vivo gene transfer for genetic disease using AAV: progress and challenges. Nature Reviews Genetics, 12(5), 341-355. [DOI: 10.1038/nrg2988]
[30] Ginn, S. L., Amaya, A. K., Alexander, I. E., & Edelstein, M. (2018). Gene therapy clinical trials worldwide to 2017: An update. Journal of Gene Medicine, 20(5), e3015. [DOI: 10.1002/jgm.3015].
[31] Mingozzi, F., & High, K. A. (2013). Immune responses to AAV vectors: overcoming barriers to successful gene therapy. Blood, 122(1), 23-36.
[32] Doudna, J. A., & Charpentier, E. (2014). The new frontier of genome engineering with CRISPR-Cas9. Science, 346(6213), 1258096.
[33] George, L. A., & Ragni, M. V. (2016). Gene therapy for bleeding and thrombotic diseases. Annual Review of Medicine, 67, 151-167.
[34] Mingozzi, F., & High, K. A. (2011). Therapeutic in vivo gene transfer for genetic disease using AAV: progress and challenges. Nature Reviews Genetics, 12(5), 341-355.
[35] Ginn, S. L., Amaya, A. K., Alexander, I. E., & Edelstein, M. (2018). Gene therapy clinical trials worldwide to 2017: An update. The Journal of Gene Medicine, 20(5), e3015.
[36] Komor, A. C., Kim, Y. B., Packer, M. S., Zuris, J. A., & Liu, D. R. (2016). Programmable editing of a target base in genomic DNA without double-stranded DNA cleavage. Nature, 533(7603), 420-424. [DOI: 10.1038/nature17946]
[37] Ginn, S. L., Amaya, A. K., Alexander, I. E., & Edelstein, M. (2018). Gene therapy clinical trials worldwide to 2017: An update. Journal of Gene Medicine, 20(5), e3015. [DOI: 10.1002/jgm.3015]
[38] Naldini, L. (2015). Gene therapy returns to centre stage. Nature, 526(7573), 351-360. [DOI: 10.1038/nature15818]
[39] Wang, M., Zuris, J. A., Meng, F., Rees, H., Sun, S., Deng, P., ... & Yao, X. (2016). Efficient delivery of genome-editing proteins using bioreducible lipid nanoparticles. Proceedings of the National Academy of Sciences, 113(11), 2868-2873. [DOI: 10.1073/pnas.1600105113]
[40] FDA News Release. (2020). FDA approves novel gene therapy to treat patients with a rare form of inherited vision loss. [Link: https://www.fda.gov/news-events/press-announcements/fda-approves-novel- gene-therapy-treat-patients-rare-form-inherited-vision-loss]
[41] Dunbar, C.E., High, K.A., Joung, J.K., Kohn, D.B., Ozawa, K., & Sadelain, M. (2018). Gene therapy comes of age. *Science*, 359(6372). doi:10.1126/science.aan4672.
[42] Maguire, A.M., High, K.A., Auricchio, A., Wright, J.F., Pierce, E.A., Testa, F., ... & Bennett, J. (2019). Age-dependent effects of RPE65 gene therapy for Leber's congenital amaurosis: a phase 1 dose- escalation trial. *Lancet*, 374(9701), 1597-1605. doi:10.1016/S0140-6736(09)61836-5.